SLC6A4 and heart valve disorder: However, new clinical and pharmacological evidence have raised concern about their potential association with valvular heart disease (VHD), which may be mediated by inhibition of the serotonin transporter (SERT) and activation of the 5-hydroxytryptamine receptor 2B (5-HT<sub>2</sub>B receptor).